Inhibitory anti-FVIII antibody formation renders treatment of hemophilia A patients ineffective, representing the most severe complication, resulting in the need for new therapies with bypassing agents and cumbersome and expensive immune tolerance induction protocols [16,17]. This evidence concerns the gene F8 and hemophilia A.